Clearside Biomedical Files 8-K Amid Listing Concerns
Ticker: CLSDQ · Form: 8-K · Filed: Nov 25, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $50,000,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, bankruptcy, listing-standards
Related Tickers: CSD
TL;DR
Clearside Biomedical (CSD) filed an 8-K flagging potential bankruptcy or delisting. Big trouble brewing.
AI Summary
Clearside Biomedical, Inc. filed an 8-K on November 25, 2025, reporting events as of November 23, 2025. The filing indicates potential issues related to bankruptcy, delisting, or failure to meet listing standards, alongside a Regulation FD disclosure and financial statements. The company is incorporated in Delaware and its principal executive offices are located in Alpharetta, Georgia.
Why It Matters
This filing suggests potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock trading status and investor confidence.
Risk Assessment
Risk Level: high — The filing explicitly mentions 'Bankruptcy or Receivership' and 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard', indicating severe financial or operational risks.
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Registrant
- November 23, 2025 (date) — Earliest event reported
- November 25, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Alpharetta, Georgia (location) — Principal executive offices
FAQ
What specific event triggered the 'Bankruptcy or Receivership' disclosure?
The filing does not specify the exact event but lists 'Bankruptcy or Receivership' as an item of information being reported.
What are the reasons for the 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'?
The filing does not detail the specific listing rule or standard Clearside Biomedical may have failed to satisfy.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 23, 2025.
What is the primary business of Clearside Biomedical, Inc.?
Clearside Biomedical, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where are Clearside Biomedical's principal executive offices located?
Clearside Biomedical's principal executive offices are located at 900 North Point Parkway, Suite 200, Alpharetta, Georgia 30005.
Filing Stats: 997 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-11-25 16:06:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
- $50,000,000 — um Market Value of Listed Securities of $50,000,000 required for continued listing on The N
Filing Documents
- d41251d8k.htm (8-K) — 29KB
- d41251dex991.htm (EX-99.1) — 32KB
- g41251g1125121304638.jpg (GRAPHIC) — 4KB
- 0001193125-25-297177.txt ( ) — 189KB
- clsd-20251123.xsd (EX-101.SCH) — 3KB
- clsd-20251123_lab.xml (EX-101.LAB) — 18KB
- clsd-20251123_pre.xml (EX-101.PRE) — 11KB
- d41251d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 25, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer